The construction of a prognostic model for colorectal cancer based on immune gene correlation and drug screening
10.19405/j.cnki.issn1000-1492.2024.05.007
- Author:
Wei Zheng
1
;
Jiajia Zhao
2
;
Xiang Cheng
1
;
Hongxin Tan
1
;
Qi Huang
1
Author Information
1. Dept of Oncology , The Second Afiliated Hospital of Anhui Medical University , Hefei 230601
2. Dept of Neurosurgery , The Second Afiliated Hospital of Anhui Medical University , Hefei 230601
- Publication Type:Journal Article
- Keywords:
colorectal cancer;
immune checkpoint inhibitors;
tumour microenvironment;
prognostic models;
immune-related genes
- From:
Acta Universitatis Medicinalis Anhui
2024;59(5):789-796
- CountryChina
- Language:Chinese
-
Abstract:
Objective :To search for new biomarkers to predict prognosis in colorectal cancer ( CRC) patients
Methods:A prognostic model was developed for colorectal cancer with immune-related genes from the cancer ge.nome atlas ( 'TCGA) database using one-way Cox regression analysis and least absolute shrinkage and selection op.erator ( L.ASS0) regression analysis. Moreover, the immune infiltration characteristics of patients in high and lowrisk groups was compared by sstimation of stromal and immune cells in malignant tumor tissues using expression data ( ESTIMATE) and cel-type identification by estimating relative subsets of RNA transcripts ( CIBERSORT). Inaddition , the expression levels of immune checkpoints were analyzed in patients from different risk groups. The sensitivity of patients in the two risk groups to chemotherapeutic agents was also compared based on genomics of drugsensitivity in cancer (GDSC).
Results:It was found that the prognostic model constructed based on immune genescould better predict the overall survival (OS) of CRC patients, and the results showed area under curve ( AUC)values of0.764(95% C1:0.751-0.793),0.773(95% C:0.761 -0.779), and 0.760(95% C:0.742 -0. 774 ) for 1-, 3-, and 5-year OS, respectively. Patients in the low-risk group had higher expression levels of immune checkpoints and more abundant immune cells such as T cells (P <0. 001), dendritic cells (P <0. 001 ),macrophages (P <0. 001), neutrophils ( P <0. 001 ). Patients in the high-risk group might be more sensitive tosome chemotherapeutic agents such as axitinib , imatinib, methotrexate, pazopanib , rapamycin, sunitinib and tasigarnib.
Conclusion:A prognostic model based on 19 immune genes was effective in predicting the prognosis ofCRC patients. The number and activity of immune cells in the immune microenvironment in different patients maybe an important factor influencing their response to immunocheck inhibitors and chemotherapeutic agents.
- Full text:2024071010215094196基于免疫基因相关的结直肠癌...后模型的构建分析及药物筛选_郑伟 (1).pdf
